Savolitinib (** Orpathys (brand name); Savolitinib (generic name) **)
Targeted Therapy
Description
Savolitinib is an investigational targeted therapy currently being studied for certain types of metastatic or unresectable colorectal cancer (CRC). It is specifically being investigated in patients whose tumors have MET amplification, a change that can help cancer cells grow and spread. The drug is taken orally, once a day, in cycles. Clinical trials are evaluating how well it shrinks tumors (objective response rate), how long the effects last (progression-free survival), and its side effects in this specific group of CRC patients. It is also being studied to see if RAS mutation status affects how well it works.
Mechanism of Action
Savolitinib is a small molecule inhibitor. It targets a specific protein involved in cell signaling pathways that control cell growth and survival. By blocking this protein, savolitinib aims to stop the signals that tell cancer cells to grow and divide, potentially slowing down or stopping the progression of the cancer. The specific protein targeted by savolitinib is being characterized in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.